News

GSK makes new drug submission for depemokimab in Canada
GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific ...
PharmTech1mon
GSK Previews Oral and Poster Abstracts for ATS International Congress
Two of the treatments that will be receiving plenty of attention in GSK’s presentations are mepolizumab and depemokimab, which are both monoclonal antibodies (mAbs) that target IL-5, a key cytokine or ...
Pharmaceutical Technology1mon
GSK remains resilient on tariffs as Q1 sales rise 4%
GSK has taken steps to boost US manufacturing amid tariff threats ... in chronic obstructive pulmonary disorder (COPD), and its new asthma biologic depemokimab.
Healio2mon
Twice-yearly depemokimab for asthma tolerated well as exacerbation rates fall
Daniel J. Jackson In the previous phase 3 SWIFT-1/2 studies, two doses of depemokimab (GSK) administered at week 0 and 26 in addition to standard of care reduced asthma exacerbations by ...
clinicaladvisor.com2mon
FDA to Review Depemokimab for Asthma With Eosinophilic Phenotype, CRSwNP
GSK. “Our SWIFT and ANCHOR trials support depemokimab’s potential to suppress interleukin-5, a known driver of type 2 inflammation, to offer patients sustained inhibition of a key driver of ...
Pharmabiz3mon
GSK’s depemokimab delivers clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps
GSK plc announced full results from the positive ANCHOR-1 and ANCHOR-2 phase III clinical trials assessing the efficacy and safety of depemokimab versus placebo (both with standard of care [SOC]) in ...
Medical Xpress3mon
Twice-yearly drug eases symptoms in chronic rhinosinusitis with polyps
sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial investigators, conducted two Phase III clinical trials to evaluate depemokimab, an ultra-long-acting anti-IL-5 biologic ...
ADVFN3mon
GSK says US FDA accepts two depemokimab indication submissions
GSK PLC on Monday said the US Food & Drug Administration has accepted for review the biologics license application fo ... Subscribe now to see this Premium News article from Alliance News ...
Finanznachrichten3mon
FDA Accepts Depemokimab Applications For Asthma With Type 2 Inflammation And CRSwNP
LONDON (dpa-AFX) - GSK plc (GSK) has announced on Monday that the FDA has accepted its Biologics License Application (BLA) for depemokimab for regulatory review in two indications. The proposed ...
Investing3mon
GSK’s depemokimab accepted by FDA for asthma, CRSwNP indications
According to InvestingPro analysis, GSK currently appears undervalued, suggesting potential upside for investors interested in this development. The applications pertain to the use of depemokimab as ...
FiercePharma3mon
Sinusitis data from Amgen, AZ's Tezspire spark 'best-in-disease' talk amid Sanofi, GSK competition
What’s more, the Tezspire data also look better than results for GSK’s depemokimab. In the phase 3 Anchor-1 and Anchor-2 trials, depemokimab’s 52-week NPS difference amounted to 0.7 points ...